BioRestorative Therapies CEO Steps Aside; Interim CEO & New CFO Appointed

What Happened

• BioRestorative Therapies, Inc. (BRTX) filed an 8‑K (Sep 2, 2026) announcing leadership changes and an auditor change. On Aug 26, 2026, Interim CEO and Secretary Katharyn Field informed the Board she would step aside; she resigned from the Board effective Aug 31, 2026 and ceased certain officer roles Aug 26–27, 2026. The Board appointed director Mika Grasso as Interim Chief Executive Officer (effective Aug 26, 2026) and on Sep 1, 2026 named Steven Brown Chairman of the Board and Audit Committee chair. On Aug 27, 2026 the Board appointed Anna Skowron as Chief Financial Officer and Treasurer (non‑employee, fractional basis through BPC Consulting Ltd.). The Board also approved indemnification agreements for Grasso, Skowron and Field on Sep 1, 2026.

Key Details

• Auditor change: CBIZ CPAs P.C. was dismissed effective Aug 28, 2026; CBIZ had served since Apr 16, 2025. CBIZ’s report for year ended Dec 31, 2025 included an explanatory paragraph expressing substantial doubt about the Company’s ability to continue as a going concern; CBIZ reported no disagreements or reportable events.
• Consulting agreements: Currensea Capital LLC (Grasso) and EEAK Consulting LLC (Field) each under consulting agreements dated Aug 27, 2026 at $10,000/month; BPC Consulting Ltd. (Skowron) at $12,000/month (all eligible for incentive/equity plans; 90‑day termination provisions).
• Board & committees: committee memberships reconstituted; Steven Brown designated audit committee financial expert.
• Timing: key corporate actions occurred Aug 26–28 and Sep 1, 2026; 8‑K filed Sep 2, 2026.

Why It Matters

• Leadership turnover and an auditor change are material governance events investors watch closely. An interim CEO and a fractional, consulting CFO indicate the company is in transition and relying on outside consultants for executive functions. The prior auditor’s going‑concern note (FY2025) is a direct signal of financial stress; dismissal of the auditor does not change that note but may affect near‑term auditing and reporting processes. The monthly consulting fees disclosed are modest relative to typical executive salaries, but investors should monitor future disclosures for any changes to financial guidance, audit firm appointment, or further governance developments.